{"id":2033,"date":"2022-05-20T00:00:00","date_gmt":"2022-05-20T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/"},"modified":"2023-06-14T20:04:07","modified_gmt":"2023-06-15T00:04:07","slug":"androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/","title":{"rendered":"Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists"},"content":{"rendered":"<p><strong>Introduction<\/strong> &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent oncological efficacy and tolerability. We investigated the proportion of physicians who predominantly prescribe one type of ADT drug (&quot;mono-prescriber&quot;) and assessed characteristics associated with prescription behavior.<\/p>\n<p><strong>Methods<\/strong> &#x2014; Ontario men aged &#x2265;65 years who were diagnosed with advanced prostate cancer (1997-2017) and initiated ADT thereafter for &#x2265;3 consecutive months were identified using population-level administrative data. Their first prescription for injectable ADT was linked to a physician, and urologists with &#x2265;10 prescriptions over the study period were included in the analysis (n=282). Urologists were classified as high mono-prescribers if &#x2265;80% of their prescriptions were for one drug type. Multivariable logistic regression was used to examine the association of physician characteristics with the odds of being a high mono-prescriber.<\/p>\n<p><strong>Results<\/strong> &#x2014; Overall, 67 (23.8%) of urologists were classified as high mono-prescribers but the frequency varied across health planning regions. The most commonly prescribed drugs and those used by mono-prescribers were goserelin (41.8% and 56.7%) and leuprolide (44.3% and 43.3%), respectively. In multivariable analysis, the odds of a physician being a high mono-prescriber were higher with more years in practice (odds ratio [OR] 1.06\/year, 95% confidence interval [CI] 1.03-1.09, p&lt;0.0001) and lower for higher patient volume (OR 0.33 for above vs. below median, 95% CI 0.17-0.63, p=0.0008).<\/p>\n<p><strong>Conclusions<\/strong> &#x2014; Overall, one in four urologists were classified as high mono-prescribers. Mono-prescribers had more years in practice and smaller volume practices, potentially suggesting habitual prescription behavior and\/or the effect of external pressures.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Introduction &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent oncological efficacy and tolerability. We investigated the proportion of physicians who predominantly prescribe one type of ADT drug (&quot;mono-prescriber&quot;) and assessed characteristics associated with prescription behavior. Methods &#x2014; Ontario men aged &#x2265;65 years who were diagnosed with [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[],"migration-helper-qa-sample-set":[],"class_list":["post-2033","journal_article","type-journal_article","status-publish","hentry"],"acf":{"citation":"Cheung DC, Martin LJ, Alibhai SMH, Komisarenko M, Dharma C, Niu Y, Warde P, Sridhar SS, Fleshner NE, Kulkarni GS, Finelli A. <em>Can Urol Assoc J<\/em>. 2022; May 20 [Epub ahead of print].","source_url":"https:\/\/cuaj.ca\/index.php\/journal\/article\/view\/7730","ices_scientist":[1147],"site":[6733],"research_program":[6741],"news_release":[],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"0C4FDE82-2E84-418F-94B7-D0E3962CE601","sitecore_item_name":"Androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors","sitecore_field_values":"{\n  \"Title\": \"Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists\",\n  \"Short title\": \"Androgen deprivation therapy for\",\n  \"Summary\": \"This study investigated the proportion of physicians who predominantly prescribe one type of ADT drug (\"mono-prescriber\") and assessed characteristics associated with prescription behavior.\",\n  \"Citation\": \"<p>Cheung DC, Martin LJ, Alibhai SMH, Komisarenko M, Dharma C, Niu Y, Warde P, Sridhar SS, Fleshner NE, Kulkarni GS, Finelli A. <em>Can Urol Assoc J<\/em>. 2022; May 20 [Epub ahead of print]. DOI: <a href=\"https:\/\/doi.org\/10.5489\/cuaj.7730\" title=\"opens external link\">https:\/\/doi.org\/10.5489\/cuaj.7730<\/a><\/p>\",\n  \"Abstract\": \"<p><strong>Introduction<\/strong> &mdash; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent oncological efficacy and tolerability. We investigated the proportion of physicians who predominantly prescribe one type of ADT drug (\"mono-prescriber\") and assessed characteristics associated with prescription behavior.<\/p>n<p><strong>Methods<\/strong> &mdash; Ontario men aged &ge;65 years who were diagnosed with advanced prostate cancer (1997-2017) and initiated ADT thereafter for &ge;3 consecutive months were identified using population-level administrative data. Their first prescription for injectable ADT was linked to a physician, and urologists with &ge;10 prescriptions over the study period were included in the analysis (n=282). Urologists were classified as high mono-prescribers if &ge;80% of their prescriptions were for one drug type. Multivariable logistic regression was used to examine the association of physician characteristics with the odds of being a high mono-prescriber.<\/p>n<p><strong>Results<\/strong> &mdash; Overall, 67 (23.8%) of urologists were classified as high mono-prescribers but the frequency varied across health planning regions. The most commonly prescribed drugs and those used by mono-prescribers were goserelin (41.8% and 56.7%) and leuprolide (44.3% and 43.3%), respectively. In multivariable analysis, the odds of a physician being a high mono-prescriber were higher with more years in practice (odds ratio [OR] 1.06\/year, 95% confidence interval [CI] 1.03-1.09, p&lt;0.0001) and lower for higher patient volume (OR 0.33 for above vs. below median, 95% CI 0.17-0.63, p=0.0008).<\/p>n<p><strong>Conclusions<\/strong> &mdash; Overall, one in four urologists were classified as high mono-prescribers. Mono-prescribers had more years in practice and smaller volume practices, potentially suggesting habitual prescription behavior and\/or the effect of external pressures.<\/p>n<p><a href=\"https:\/\/cuaj.ca\/index.php\/journal\/article\/view\/7730\" title=\"opens externallink\">View full text<\/a><\/p>\",\n  \"Research Programs\": \"{85DE96A6-4C96-40C7-8E6D-7597A0EB5F80}\",\n  \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n  \"ICES Scientists\": \"{9564D1CB-B35F-4CEC-9144-23097BB45807}\",\n  \"Posted Date\": \"20220520T000000\",\n  \"Show on Publications Landing Page\": \"1\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2022\/May\/Androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists<\/title>\n<meta name=\"description\" content=\"Introduction &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists\" \/>\n<meta property=\"og:description\" content=\"Introduction &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-15T00:04:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\\\/\",\"name\":\"ICES | Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2022-05-20T04:00:00+00:00\",\"dateModified\":\"2023-06-15T00:04:07+00:00\",\"description\":\"Introduction &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists","description":"Introduction &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists","og_description":"Introduction &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-15T00:04:07+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/","name":"ICES | Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2022-05-20T04:00:00+00:00","dateModified":"2023-06-15T00:04:07+00:00","description":"Introduction &#x2014; Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/androgen-deprivation-therapy-for-prostate-cancer-prescribing-behaviors-and-preferences-among-urologists\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/2033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6741"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1147"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=2033"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=2033"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=2033"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=2033"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=2033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}